Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

vasopharm GmbH

www.vasopharm.com

Latest From vasopharm GmbH

Finance Watch: Among Multiple Mega-Rounds, Revolution Raises $100m For RAS Programs

Private Company Edition: Revolution Medicines follows its Sanofi partnership and Warp Drive Bio buyout with a series C venture capital round to fund its RAS pathway inhibitors in cancer. The financing came during a boom in $100m-plus VC financings, including BioNTech's $325m series B.

Financing Business Strategies

Can Vasopharm Be First To EU Market With Novel TBI Drug?

Small German firm, Vasopharm, wants to be the first company to bring a therapeutic treatment to the European market for use in patients with traumatic brain injuries – but getting the drug through Phase III studies alone will be its biggest test yet.

Business Strategies Commercial

Cellvation Tackling Traumatic Brain Injuries With Stem Cell Therapy

Emerging Company Profile: With mononuclear stem cell therapy from University of Texas research, new company hopes to address traumatic brain injury by reducing the pro-inflammatory cytokine cascade, which exacerbates the initial injuries in severe TBI.

Regenerative Medicine Business Strategies

PIPELINE WATCH: Three Approvals, Five Filings And Two Launches

This week's Pipeline Watch, a snapshot of all the late-stage R&D and regulatory events in the pharma and biotech industries, is now available to view.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Neurology, Nervous System
  • Alias(es)
  • vasopharm Biotech GMBH
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • vasopharm GmbH
  • Senior Management
  • Christian Wandersee, CEO
    Frank Tegtmeier, PhD, CSO
  • Contact Info
  • vasopharm GmbH
    Phone: (49) 931 35 90 99-0
    Friedrich-Bergius-Ring 15
    Wuerzburg, 97076
    Germany
Advertisement
Advertisement
UsernamePublicRestriction

Register